Overview
Portfolio
More
Forwardasset
London, United Kingdom
Portfolio
8+
Employees
15+
Founded
2000
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United Kingdom
Sources
Forwardasset
Portfolio
8+
Employees
15+
Founded
2000
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United Kingdom
Sources
Showing 6 of 6 matched portfolio companies
The company develops anti-inflammatory, anti-fibrotic, and anti-neovascular therapies targeting CSF1R to treat diseases with significant unmet medical needs. Their technology aims to provide healthcare professionals with effective treatment options for conditions that currently lack adequate therapeutic solutions.
Funding: $39.0M
Rough estimate of the amount of funding raised
Funding: $39.0M
Rough estimate of the amount of funding raised
EmpressTX offers the Chemilogics™ platform, which uses human genetic data, AI/ML, and co‑evolutionary algorithms to generate drug‑like small molecules that are naturally encoded in the genome. By predicting and prioritizing millions of chemically diverse candidates and enabling rapid synthetic‑biology production, the platform reduces lead‑identification timelines from years to months, providing pharmaceutical and biotech companies with biologically validated starting points for drug development.
Funding: $50.0M
Rough estimate of the amount of funding raised
Funding: $50.0M
Rough estimate of the amount of funding raised
GeneFab provides contract development and manufacturing services for cell and gene therapies, utilizing expertise in gene-to-cell design and optimization to enhance product manufacturability. The company addresses the challenges faced by innovators in bringing novel therapies to clinical application by offering flexible tech operations and transparent project management throughout the drug development lifecycle.
The startup develops immunotherapy drugs and vaccines specifically for companion animals, focusing on targeted treatments for canine cancer. By utilizing advanced immunological techniques, the company aims to improve the efficacy of cancer therapies and enhance the quality of life for pets suffering from this disease.
TAI offers a mobile application that enables users to manage and optimize their investment portfolios through real-time analytics and performance tracking. The platform addresses the challenge of fragmented investment management by providing a unified interface for monitoring asset performance and making informed decisions.
Founded 2021100+
Funding: $500.0K
Rough estimate of the amount of funding raised
Funding: $500.0K
Rough estimate of the amount of funding raised
YAN provides a unified digital platform combining banking services with an e-commerce marketplace and bill payment features. Through a single "Super App," users can manage finances, shop for goods and services, and pay bills in one integrated ecosystem.
Showing 2 of 2 unmatched portfolio companies